Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Specific Device Cost Data May Inform Medicare Inpatient Payments In FY 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS says it is finally ready to start relying on a specific cost-report line that it created five years ago for implantable devices, as well as distinct lines for cardiac catheterizations, CT scans and MRIs established more recently, to calculate hospital inpatient payments. It’s a positive for implantables and a negative for advanced imaging payments.

You may also be interested in...



CMS Tinkers With Readmissions Policy, Other Quality Initiatives

The agency plans to be more selective about which hospital readmissions count toward a potential payment reduction in fiscal year 2014, according to its inpatient payment proposal. CMS also proposes hip and knee replacements as a new category of hospital admission to be included in the readmissions reduction program.

CMS Moves Forward With Addressing Charge Compression For Implantable Devices

The agency finalized its decision to base its payment calculations on data that separates hospital charges for implantable devices from those for lower-priced medical supplies in the final 2013 outpatient rule.

Industry To CMS: Accelerate Charge Compression Solutions

CMS is putting off for at least one more year plans to factor data into its reimbursement calculations that companies believe will lead to fairer payment rates for implantable devices. Some in industry are demanding more action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel